About Us
Abliva – Delivering mitochondrial healthAbliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).
Contacts
-
Catharina Johansson
CFO, IR & Communications
Medicon Village 223 81 Lund Sweden
+46 (0)46-275 62 21
http://www.abliva.com
ir@abliva.com -
Abliva
+46 (0)46 275 62 20
info@abliva.com